CA3085455A1 - Forme pharmaceutique orale solide comprenant de la linagliptine - Google Patents

Forme pharmaceutique orale solide comprenant de la linagliptine Download PDF

Info

Publication number
CA3085455A1
CA3085455A1 CA3085455A CA3085455A CA3085455A1 CA 3085455 A1 CA3085455 A1 CA 3085455A1 CA 3085455 A CA3085455 A CA 3085455A CA 3085455 A CA3085455 A CA 3085455A CA 3085455 A1 CA3085455 A1 CA 3085455A1
Authority
CA
Canada
Prior art keywords
dosage form
oral dosage
solid oral
weight
linagliptin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA3085455A
Other languages
English (en)
Other versions
CA3085455C (fr
Inventor
Ali Turkyilmaz
Nur PEHLIVAN AKALIN
Merve ERGUN DONMEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Publication of CA3085455A1 publication Critical patent/CA3085455A1/fr
Application granted granted Critical
Publication of CA3085455C publication Critical patent/CA3085455C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une forme pharmaceutique orale solide comprenant de la linagliptine et au moins un liant.
CA3085455A 2017-12-15 2018-12-14 Forme pharmaceutique orale solide comprenant de la linagliptine Active CA3085455C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TR2017/20515 2017-12-15
TR2017/20515A TR201720515A2 (tr) 2017-12-15 2017-12-15 Li̇nagli̇pti̇n i̇çeren bi̇r kati oral dozaj formu
PCT/TR2018/050812 WO2019203755A2 (fr) 2017-12-15 2018-12-14 Forme pharmaceutique orale solide comprenant de la linagliptine

Publications (2)

Publication Number Publication Date
CA3085455A1 true CA3085455A1 (fr) 2019-10-24
CA3085455C CA3085455C (fr) 2022-08-16

Family

ID=67900883

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3085455A Active CA3085455C (fr) 2017-12-15 2018-12-14 Forme pharmaceutique orale solide comprenant de la linagliptine

Country Status (4)

Country Link
EP (1) EP3723761A4 (fr)
CA (1) CA3085455C (fr)
TR (1) TR201720515A2 (fr)
WO (1) WO2019203755A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022173406A1 (fr) * 2021-02-15 2022-08-18 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Procédé pour formulations de linagliptine ou d'un sel pharmaceutiquement acceptable de celle-ci
WO2024136773A1 (fr) * 2022-12-21 2024-06-27 Santa Farma Ilac Sanayii A.S. Composition pharmaceutique stable comprenant de la linagliptine
WO2025144125A1 (fr) * 2023-12-27 2025-07-03 Santa Farma Ilac Sanayii A.S. Composition pharmaceutique stable présentant un meilleur profil d'impureté génotoxique

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32427A (es) * 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
WO2013128379A2 (fr) 2012-02-27 2013-09-06 Dr. Reddy's Laboratories Limited Formes polymorphes cristallines de linagliptine
WO2014056942A1 (fr) * 2012-10-09 2014-04-17 Boehringer Ingelheim International Gmbh Utilisation de matière à fabriquer les comprimés dont on ajuste sélectivement l'humidité dans la production de comprimés mécaniquement stables qui contiennent au moins une substance active formant un hydrate et/ou un adjuvant lié à la stabilité mécanique des comprimés, en particulier des comprimés contenant de l'arginine
WO2014080384A1 (fr) 2012-11-26 2014-05-30 Ranbaxy Laboratories Limited Composition pharmaceutique de linagliptine
WO2014080383A1 (fr) * 2012-11-26 2014-05-30 Ranbaxy Laboratories Limited Composition pharmaceutique d'inhibiteurs de la dipeptidyl-peptidase-iv (dpp-iv) en association avec d'autres antidiabétiques
CN106138059A (zh) 2015-03-27 2016-11-23 天津汉瑞药业有限公司 一种稳定的利格列汀药物组合物
EP3156048A1 (fr) 2015-10-13 2017-04-19 Galenicum Health S.L. Composition pharmaceutique stable de linagliptine sous forme de comprimé à libération immédiate

Also Published As

Publication number Publication date
WO2019203755A3 (fr) 2020-01-16
WO2019203755A2 (fr) 2019-10-24
CA3085455C (fr) 2022-08-16
EP3723761A2 (fr) 2020-10-21
TR201720515A2 (tr) 2019-07-22
EP3723761A4 (fr) 2021-06-30

Similar Documents

Publication Publication Date Title
AU2005249467B2 (en) Coated tablet formulation and method
JP2009526047A (ja) モンテルカストナトリウムの安定な医薬製剤
US11819577B2 (en) Fixed dose pharmaceutical composition of valsartan and sacubitril
EP3731837A2 (fr) Combinaison contenant de la linagliptine et de la metformine
US20190110994A1 (en) Pharmaceutical composition of dapagliflozin
EP3781135A2 (fr) Compositoins pharmaceutiques solides d'administration par voie orale comprenant de la sitagliptine
CA3085455C (fr) Forme pharmaceutique orale solide comprenant de la linagliptine
WO2014080384A1 (fr) Composition pharmaceutique de linagliptine
EP2468268B1 (fr) Composition de combinaison de vildagliptine et de gliclazide
WO2017208136A1 (fr) Composition pharmaceutique de co-cristal de dapagliflozine
EP3801539B1 (fr) Compositoins pharmaceutiques solides d'administration par voie orale comprenant de la linagliptine
WO2019132833A1 (fr) Combinaison à libération modifiée comprenant de la linagliptine et de la metformine
EP4008317A1 (fr) Formulations pharmaceutiques solides de dapagliflozine amorphe
WO2020109319A1 (fr) Composition pharmaceutique comprenant du ramipril et de l'indapamide
EP3731931B1 (fr) Formulations à libération modifiée de fésotérodine
WO2005030219A1 (fr) Procede de stabilisation d'un compose diarylvinylene
US20240315978A1 (en) Pharmaceutical compositions comprising acalabrutinib
EP2468267B1 (fr) Composition de combinaison bicouche de vildagliptine et de gliclazide
WO2022173406A1 (fr) Procédé pour formulations de linagliptine ou d'un sel pharmaceutiquement acceptable de celle-ci
WO2024084496A1 (fr) Compositions pharmaceutiques comprenant du maléate d'acalabrutinib
TR201703066A2 (tr) İvabradi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari
WO2025144305A2 (fr) Formulations pharmaceutiques à libération prolongée comprenant de la linagliptine et de la metformine
WO2022029798A1 (fr) Compositions pharmaceutiques comprenant du ribociclib
TR2021002097A2 (tr) Li̇nagli̇pti̇n ya da onun farmasöti̇k olarak kabul edi̇lebi̇li̇r bi̇r tuzunun formülasyonlari i̇çi̇n bi̇r proses
JP2020075923A (ja) エルロチニブを有効成分とする医薬錠剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200610

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250917

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251230

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260204

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260205